Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Arcturus Therapeutics Holdings Inc

Healthcare US ARCT

7.01USD
-0.07(0.99%)

Last update at 2026-06-24T20:00:00Z

Day Range

6.977.38
LowHigh

52 Week Range

5.8524.17
LowHigh

Fundamentals

  • Previous Close 7.08
  • Market Cap250.69M
  • Volume523335
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-73.23500M
  • Revenue TTM82.03M
  • Revenue Per Share TTM3.00
  • Gross Profit TTM -30.18100M
  • Diluted EPS TTM-2.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -65.78300M -80.94500M -27.89000M 10.64M -203.67400M
Minority interest - - - - -
Net income -65.78300M -80.94100M -29.72500M 9.35M -206.86300M
Selling general administrative 46.08M 52.82M 52.87M 46.07M 41.45M
Selling and marketing expenses - - 2.96M - -
Gross profit 64.20M 138.39M 157.75M 205.75M 12.36M
Reconciled depreciation 3.02M 3.54M 2.69M 1.53M 1.19M
Ebit -74.95500M -80.94500M -27.12200M 12.18M -202.85200M
Ebitda -71.93000M -77.40100M -24.16500M 11.66M -200.39100M
Depreciation and amortization 3.02M 3.54M 2.96M -0.51500M 2.46M
Non operating income net other - - - - -0.82200M
Operating income -74.95500M -95.66900M -78.20500M 12.18M -202.85200M
Other operating expenses 142.18M 234.06M 235.95M 193.58M 215.21M
Interest expense 0.00900M 0.00000M 0.77M 0.42M 2.67M
Tax provision 0.00000M -0.00400M 2.87M 1.29M -
Interest income 10.10M 15.20M 12.29M 2.58M 0.75M
Net interest income 10.10M 15.20M 10.73M -0.42000M -1.92100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -75.87800M -0.00400M 1.83M 1.29M 3.19M
Total revenue 67.22M 138.39M 157.75M 205.75M 12.36M
Total operating expenses 139.15M 234.06M 235.95M 193.58M 215.21M
Cost of revenue 3.02M 3.54M 2.96M - -
Total other income expense net 9.17M 14.72M 50.31M -1.53300M -0.82200M
Discontinued operations - - - - -
Net income from continuing ops -65.78300M -80.94100M 99.33M 9.35M -203.67400M
Net income applicable to common shares - - - 9.35M -203.67400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 271.15M 344.07M 429.40M 450.39M 392.81M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.97M 64.98M 7.52M 8.69M 5.10M
Total liab 57.16M 103.09M 150.89M 180.07M 164.60M
Total stockholder equity 213.99M 240.98M 278.51M 270.31M 228.21M
Deferred long term liab - - - - 19.93M
Other current liab 19.68M 32.81M 25.06M 30.23M 23.52M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -514.59000M -448.80700M -367.86600M -338.14100M -347.49000M
Other liab - - - 22.88M 19.93M
Good will - - - - -
Other assets - - - - 2.08M
Cash 230.91M 237.03M 347.00M 391.88M 370.49M
Cash and equivalents - - - - -
Total current liabilities 36.38M 65.49M 81.99M 126.98M 99.54M
Current deferred revenue 8.25M 21.93M 47.34M 28.65M 43.48M
Net debt -205.91100M -208.47800M -316.78900M -301.01200M -302.88300M
Short term debt 4.21M 3.55M 4.31M 60.66M 22.47M
Short long term debt - - - 60.66M 22.47M
Short long term debt total 25.00M 28.55M 30.22M 90.87M 67.61M
Other stockholder equity 728.55M 689.76M 646.35M 608.43M 575.67M
Property plant equipment - - - 44.96M 11.26M
Total current assets 241.45M 305.98M 386.59M 403.33M 378.96M
Long term investments - - - 0.00000M 0.52M
Net tangible assets - - - - 228.21M
Short term investments - - - - -
Net receivables 5.56M 3.97M 32.06M 2.76M 3.37M
Long term debt - - - - 40.63M
Inventory - - 0.00000M - -
Accounts payable 4.24M 7.19M 5.28M 7.45M 10.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -347.49000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.89M 1.89M 1.89M 2.09M 2.08M
Deferred long term asset charges - - - - -
Non current assets total 29.70M 38.09M 42.81M 47.05M 13.85M
Capital lease obligations 25.00M 28.55M 30.22M 34.10M 6.04M
Long term debt total - - - - 40.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.64800M -5.83300M -7.72600M -3.40600M
Change to liabilities - - - 0.00000M 32.02M
Total cashflows from investing activities -0.23000M -0.64800M -2.90100M -7.72600M -3.40600M
Net borrowings 0.00000M 0.00000M -27.36400M -5.00000M 46.60M
Total cash from financing activities 13.38M 5.42M -24.08700M -2.85900M 48.02M
Change to operating activities - - - - 0.45M
Net income -65.78300M -80.94100M -29.72500M 9.35M -203.67400M
Change in cash -61.11900M -54.97700M -45.08700M 21.41M -90.43300M
Begin period cash flow 293.91M 348.89M 393.98M 372.57M 463.00M
End period cash flow 232.79M 293.91M 348.89M 393.98M 372.57M
Total cash from operating activities -74.27100M -59.74700M -18.09900M 31.99M -135.04300M
Issuance of capital stock 12.27M 0.68M 0.61M 0.41M 0.52M
Depreciation 3.02M 3.54M 2.96M 1.53M 1.19M
Other cashflows from investing activities -0.23000M -0.64800M - - -
Dividends paid - - - - -
Change to inventory - - - - 0.45M
Change to account receivables -1.59000M 28.09M -29.30000M 0.60M -1.24200M
Sale purchase of stock - - - - 1.42M
Other cashflows from financing activities 13.38M 4.74M 2.67M 1.73M 47.50M
Change to netincome - - - - 36.20M
Capital expenditures 0.23M 0.65M 2.90M 7.73M 3.41M
Change receivables - - - - -1.24200M
Cash flows other operating - - - - 29.95M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -90.43300M
Change in working capital -39.20000M -20.80900M 7.38M -12.55700M 31.23M
Stock based compensation 25.41M 37.99M 34.65M 30.61M 28.91M
Other non cash items 2.28M 0.47M -33.36100M 3.06M 8.38M
Free cash flow -74.27100M -60.39500M -21.00000M 24.27M -138.44900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARCT
Arcturus Therapeutics Holdings Inc		 -0.07 0.99% 7.01 - 2.48 3.06 1.18 0.70 -25.6651
NVO
Novo Nordisk A/S		 -0.01 0.02% 47.41 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.40 0.87% 623.43 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc

10285 Science Center Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Joseph E. Payne M.Sc. Founder, Pres, CEO & Director 1972
Dr. Padmanabh Chivukula Founder, Chief Scientific Officer, COO & Sec. 1979
Mr. Andrew H. Sassine MBA CFO & Director 1964
Mr. Lance Kurata Chief Legal Officer NA
Dr. Steven George Hughes M.B.A., M.D. Strategic Clinical Advisor & Member of Scientific Advisory Board 1968
Mr. Keith C. Kummerfeld CPA VP of Fin. & Corp. Controller NA
Dr. Dushyant B. Varshney Ph.D. Exec. VP & Chief Technology Officer NA
Mr. Deepankar Roy Sr. Director of Investor Relations NA
Kyle Gutstadt Sr. Analyst of Investor & PR NA
Mr. Kevin T. Skol Sr. VP of Bus. Devel. & Alliance Management NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions